CY1110263T1 - Νεες ενωσεις ισοξαζολης και θειαζολης και η χρηση τους ως φαρμακα - Google Patents

Νεες ενωσεις ισοξαζολης και θειαζολης και η χρηση τους ως φαρμακα

Info

Publication number
CY1110263T1
CY1110263T1 CY20091100377T CY091100377T CY1110263T1 CY 1110263 T1 CY1110263 T1 CY 1110263T1 CY 20091100377 T CY20091100377 T CY 20091100377T CY 091100377 T CY091100377 T CY 091100377T CY 1110263 T1 CY1110263 T1 CY 1110263T1
Authority
CY
Cyprus
Prior art keywords
group
atom
isoxazol
thiazol
medicines
Prior art date
Application number
CY20091100377T
Other languages
English (en)
Inventor
Akihiro Ueno
Rika Nagao
Tomoko Watanabe
Hideo Ohta
Mikio Yagi
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of CY1110263T1 publication Critical patent/CY1110263T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέες ενώσεις ισοξαζόλης και θειαζόλης που έχουν μια εξαιρετική ανταγωνιστική δραστηριότητα στον υποδοχέα του λυσοφωσφατιδικού οξέος (LPA) που αντιπροσωπεύεται από τον γενικό τύπο [1] ή άλατα τους όπου R1 και R2 αντιπροσωπεύουν μια προαιρετικά υποκαθιστάμενη αλκυλ ομάδα ή τα παρόμοια, R3 αντιπροσωπεύει ένα άτομο υδρογόνου ή τα παρόμοια, R4 αντιπροσωπεύει μια ομάδα που επιλέγεται από την ομάδα η οποία συνίσταται από (I) προαιρεταικά υποκαθιστάμενο φαινυλ, αρυλ, ή ετερόκυκλο, (II) υποκαθιστάμενο ή μη υπκαθιστάμενο αλκυλ, και (III) υποκαθιστάμενο ή μη υπκαθιστάμενο αλκενυλ, εναλλακτικά, R3 και R4 μπορούν να σχηματίζουν μια δομή δακτυλίου μαζί με ένα άτομο άνθρακα στο οποίο συνδέονται, και Χ αντιπροσωπεύει ένα άτομο οξυγόνου ή ένα άτομο θείου, με την προϋπόθεση ότι, όταν R3 είναι ένα άτομο υδρογόνου, R4 αντιπροσωπεύει μια ομάδα άλλη από μεθυλ, και η χρήση τους ως ένα φάρμακο.
CY20091100377T 2000-02-18 2009-03-31 Νεες ενωσεις ισοξαζολης και θειαζολης και η χρηση τους ως φαρμακα CY1110263T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000041922 2000-02-18
EP01904545A EP1258484B1 (en) 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs

Publications (1)

Publication Number Publication Date
CY1110263T1 true CY1110263T1 (el) 2015-01-14

Family

ID=18565067

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100377T CY1110263T1 (el) 2000-02-18 2009-03-31 Νεες ενωσεις ισοξαζολης και θειαζολης και η χρηση τους ως φαρμακα

Country Status (11)

Country Link
US (1) US6964975B2 (el)
EP (1) EP1258484B1 (el)
AT (1) ATE420878T1 (el)
AU (1) AU2001232340A1 (el)
CY (1) CY1110263T1 (el)
DE (1) DE60137405D1 (el)
DK (1) DK1258484T3 (el)
ES (1) ES2320320T3 (el)
PT (1) PT1258484E (el)
TW (1) TWI288136B (el)
WO (1) WO2001060819A1 (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
CA2437358A1 (en) 2001-01-30 2002-08-22 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ATE406915T1 (de) * 2001-07-17 2008-09-15 Ono Pharmaceutical Co Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
AU2003241833A1 (en) * 2002-05-28 2003-12-12 Ono Pharmaceutical Co., Ltd. Beta-ALANINE DERIVATIVE AND USE THEREOF
JPWO2004002530A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 慢性疾患治療剤
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7524638B1 (en) 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
AU2006214314B2 (en) 2005-02-14 2012-02-09 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2009528274A (ja) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
JP2010510251A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体活性を有するベンゾシクロヘプチルアナログ
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
NZ588807A (en) * 2008-05-05 2011-07-29 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
TW201117809A (en) 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011159632A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
CN102985405B (zh) * 2010-07-02 2016-07-06 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
PL2648726T3 (pl) * 2010-12-07 2018-10-31 Amira Pharmaceuticals, Inc. Policykliczny antagonista lpa1 i jego zastosowania
CN103443098B (zh) * 2011-01-30 2016-03-16 广州源生医药科技有限公司 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用
JP2014513077A (ja) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
SG195110A1 (en) * 2011-05-25 2013-12-30 Intermune Inc Pirfenidone and anti-fibrotic therapy in selected patients
CN104066729A (zh) 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013078283A1 (en) 2011-11-22 2013-05-30 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
JP2015521183A (ja) * 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
RU2649398C2 (ru) * 2012-12-28 2018-04-03 Убе Индастриз, Лтд. Галогензамещенное гетероциклическое соединение
SG10201803833WA (en) 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
EA038294B1 (ru) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
CN104788343A (zh) * 2014-01-16 2015-07-22 同济大学 一种邻位取代烯丙基氨基甲酸酯类化合物及其制备方法
KR102433588B1 (ko) * 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
HRP20211918T8 (hr) 2017-12-19 2022-04-15 Bristol-Myers Squibb Company Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
ES2925626T3 (es) 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN111479807A (zh) 2017-12-19 2020-07-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
EP3728242B1 (en) 2017-12-19 2023-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
CA3104465A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
WO1998027213A1 (en) * 1996-12-18 1998-06-25 Medical Research Council Lysophosphatidic acid acyltransferase gene and its use
SE9904044D0 (sv) * 1999-11-09 1999-11-09 Astra Ab Compounds
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Also Published As

Publication number Publication date
US6964975B2 (en) 2005-11-15
DK1258484T3 (da) 2009-04-20
WO2001060819A1 (fr) 2001-08-23
DE60137405D1 (de) 2009-03-05
ATE420878T1 (de) 2009-01-15
EP1258484A1 (en) 2002-11-20
ES2320320T3 (es) 2009-05-21
US20030114505A1 (en) 2003-06-19
AU2001232340A1 (en) 2001-08-27
EP1258484B1 (en) 2009-01-14
TWI288136B (en) 2007-10-11
PT1258484E (pt) 2009-04-03
EP1258484A4 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
CY1110263T1 (el) Νεες ενωσεις ισοξαζολης και θειαζολης και η χρηση τους ως φαρμακα
BRPI0213243B8 (pt) composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
ATE542805T1 (de) Ppar-delta aktivatoren
FI943561A (fi) Uudet ainekoostumukset
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
HRP20030281B1 (en) Pesticidal composition
WO2003016291A1 (fr) Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
ATE103592T1 (de) Carbamoylpyrrolidonderivate, ihre verwendung und herstellung.
ATE323087T1 (de) Aryl substituierte oxazolidinone mit antibacterieller activität
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
NO20055695L (no) Tiadiazinforbindelser og anvendelse derav som positive AMPA-reseptormodulatorer
ATE525366T1 (de) Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
CA2371827A1 (en) Amide compounds for the potentiation of cholinergic activity
CO5150201A1 (es) Derivados de piperidina
SE7605190L (sv) Nya tiazoliner
BR9508676A (pt) Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições
ATE109475T1 (de) Benzothiazolinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
BR9608929A (pt) Derivados de hidroxilamina anti-isquêmicos e composições farmacêuticas
BR8003950A (pt) Composicoes herbicidas, baseadas em derivados de m-anilido-uretana
ATE122040T1 (de) Pestizide heterozyklische verbindungen.
TW200626007A (en) Material for electroluminescent element and electroluminescent element